BRPI1015216A2 - método de tratar ou prevenir uma condição médica em um indivíduo. - Google Patents

método de tratar ou prevenir uma condição médica em um indivíduo.

Info

Publication number
BRPI1015216A2
BRPI1015216A2 BRPI1015216A BRPI1015216A BRPI1015216A2 BR PI1015216 A2 BRPI1015216 A2 BR PI1015216A2 BR PI1015216 A BRPI1015216 A BR PI1015216A BR PI1015216 A BRPI1015216 A BR PI1015216A BR PI1015216 A2 BRPI1015216 A2 BR PI1015216A2
Authority
BR
Brazil
Prior art keywords
treating
preventing
individual
medical condition
medical
Prior art date
Application number
BRPI1015216A
Other languages
English (en)
Inventor
Christopher Winter
Michael Chastain
Shailaja Kasibhatla
Sriram Sathyanarayanan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI1015216A2 publication Critical patent/BRPI1015216A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BRPI1015216A 2009-04-16 2010-04-06 método de tratar ou prevenir uma condição médica em um indivíduo. BRPI1015216A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16976809P 2009-04-16 2009-04-16
PCT/US2010/030022 WO2010120592A1 (en) 2009-04-16 2010-04-06 Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors

Publications (1)

Publication Number Publication Date
BRPI1015216A2 true BRPI1015216A2 (pt) 2016-04-12

Family

ID=42982796

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015216A BRPI1015216A2 (pt) 2009-04-16 2010-04-06 método de tratar ou prevenir uma condição médica em um indivíduo.

Country Status (18)

Country Link
US (1) US20120058112A1 (pt)
EP (1) EP2419135A4 (pt)
JP (1) JP2012524087A (pt)
KR (1) KR20110140126A (pt)
CN (1) CN102458466A (pt)
AU (1) AU2010236818B2 (pt)
BR (1) BRPI1015216A2 (pt)
CA (1) CA2757730A1 (pt)
CL (1) CL2011002569A1 (pt)
CO (1) CO6571849A2 (pt)
EC (1) ECSP11011405A (pt)
IL (1) IL215363A0 (pt)
MX (1) MX2011010911A (pt)
NZ (1) NZ595755A (pt)
RU (1) RU2011146339A (pt)
SG (1) SG175208A1 (pt)
WO (1) WO2010120592A1 (pt)
ZA (1) ZA201107204B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
US8470297B1 (en) * 2009-09-10 2013-06-25 Merck Sharp & Dohme Corp. FDG-pet evaluation of Ewing's sarcoma sensitivity
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
GB201409488D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CN105963305B (zh) * 2016-07-05 2018-08-17 福州大学 一种含酪氨酸激酶抑制剂的药物组合物及其在制备抗肿瘤转移药物中的应用
CN105998033B (zh) * 2016-07-05 2018-11-27 福州大学 一种含有厄洛替尼和熊果酸的药物组合物及其在制备抗肿瘤药物中的应用
CA3237041A1 (en) * 2021-11-02 2023-05-11 Fusion Pharmaceuticals Inc. Methods of treating cancer
WO2023235822A1 (en) * 2022-06-03 2023-12-07 Foundation Medicine, Inc. Igf1r activation mutations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
EP2236139A1 (en) * 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor

Also Published As

Publication number Publication date
ECSP11011405A (es) 2011-11-30
AU2010236818A1 (en) 2011-11-03
RU2011146339A (ru) 2013-05-27
KR20110140126A (ko) 2011-12-30
CA2757730A1 (en) 2010-10-21
NZ595755A (en) 2013-07-26
US20120058112A1 (en) 2012-03-08
CL2011002569A1 (es) 2012-04-09
AU2010236818B2 (en) 2014-03-13
CO6571849A2 (es) 2012-11-30
EP2419135A4 (en) 2012-11-28
JP2012524087A (ja) 2012-10-11
SG175208A1 (en) 2011-11-28
ZA201107204B (en) 2015-07-29
WO2010120592A1 (en) 2010-10-21
IL215363A0 (en) 2011-12-29
EP2419135A1 (en) 2012-02-22
CN102458466A (zh) 2012-05-16
MX2011010911A (es) 2011-11-02

Similar Documents

Publication Publication Date Title
BRPI1008628A2 (pt) método de tratamento ou prevenção de arritmia cardíaca em um indivíduo
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0920498A2 (pt) método de tratamento de uma condição em um sujeito
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
FI20095553A0 (fi) Jätteenkäsittelyjärjestelmä ja menetelmä
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1014824A2 (pt) composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo
BRPI1007996A2 (pt) fluido de tratamento, e, método
BR112013012485A2 (pt) método de tratamento com inibidor braf
BRPI0910854A2 (pt) métodos de tratamento
HK1185908A1 (en) Polymer treatment method
BRPI1015216A2 (pt) método de tratar ou prevenir uma condição médica em um indivíduo.
EP2621420A4 (en) CORNEAL TREATMENT SYSTEM AND METHOD
EP2432476A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
IL212348A0 (en) Treatment method
BRPI0822633A2 (pt) Desinfetante, e, método de esterilização.
BR112013013584A2 (pt) endoscópio, e, método
FI20095554A (fi) Menetelmä ja väline jätteenkäsittelyssä
BR112012021071A2 (pt) método de tratamento do solo, aparelho de injeção, cabeçote do aparelho de injeção e combinação
BR112013009294A2 (pt) componente dental, fixação dental, conjunto de implante dental e sistema de implante dental
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
BR112012002571A2 (pt) tratamento de minérios de titânio
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
BR112012000095A2 (pt) método de tratamento ou prevenção de ponv ou pdnv
EP2465458A4 (en) MEDICAL TREATMENT INSTRUMENT, MEDICAL TREATMENT DEVICE, AND MEDICAL TREATMENT METHOD

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.